Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 105 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Old Age; Dementia Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

NCT00959803
View directory record Official record
Conditions
Healthy
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Oct 4, 2026, 9:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

NCT04798989
View directory record Official record
Conditions
Alzheimer's Disease With Vascular Pathology
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease

NCT01928420
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: NIC5-15, Placebo
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
40 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of ABT-126 in Elderly

NCT00867399
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-126
Drug
Lead sponsor
Abbott
Industry
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Not applicable Interventional Results available

Zolpidem CR and Hospitalized Patients With Dementia

NCT00814502
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation
Interventions
Zolpidem CR, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 4, 2026, 9:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias

NCT01730430
View directory record Official record
Conditions
Alzheimer's Disease, Dementias
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
55 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Oct 4, 2026, 9:41 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

NCT06919926
View directory record Official record
Conditions
Hippocampal Overactivity, Dementia
Interventions
AGB101, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

NCT01565291
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • North East, Maryland • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study GSI-136 in Healthy Young and Healthy Elderly Subjects

NCT00718731
View directory record Official record
Conditions
Alzheimer Disease, Healthy
Interventions
GSI-136, Placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Not applicable Interventional

Orexin and Tau Pathology in Cognitively Normal Elderly

NCT03053908
View directory record Official record
Conditions
Elderly, Alzheimer Disease
Interventions
Actigraphy, Nocturnal Polysomnograpahy (NPSG)
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 4, 2026, 9:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

NCT04732182
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease
Device · Drug
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
65 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Brunswick, New Jersey • North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Not applicable Interventional Results available

A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease

NCT05147428
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Educational Materials
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
50 Years and older
Enrollment
14,442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 4, 2026, 9:41 PM EDT
Terminated Phase 3 Interventional

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

NCT00160147
View directory record Official record
Conditions
Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Interventions
bifeprunox, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
65 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Carson, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

NCT01503944
View directory record Official record
Conditions
Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease
Interventions
18F-AV-133, 18F-AV-45
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Sun City, Arizona • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Oct 4, 2026, 9:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Elderly People and Individuals With Alzheimer's Disease

NCT00001917
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
O15, [F-18] FP-TZTP
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 9:41 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

NCT06546995
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Elderly
Interventions
NMRA-323511, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Chandler, Arizona • Tempe, Arizona • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 4, 2026, 9:41 PM EDT
Completed No phase listed Observational

The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)

NCT03692182
View directory record Official record
Conditions
Behavioral and Psychiatric Symptoms of Dementia
Interventions
Not listed
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
55 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Moorestown, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

NCT00742417
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albutein 5%, Control
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Whiting, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 4, 2026, 9:41 PM EDT
Terminated No phase listed Observational

Dementia Management With Interactive Technology

NCT03916588
View directory record Official record
Conditions
Dementia, Memory Disorders in Old Age
Interventions
Individualized Care Plan
Behavioral
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
89 participants
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Not applicable Interventional Results available

Nursing Home Prevention of Injury in Dementia (NH PRIDE)

NCT04242186
View directory record Official record
Conditions
Accidental Falls/Prevention and Control
Interventions
Injury Liaison Service
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
60 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

NCT00547560
View directory record Official record
Conditions
Healthy
Interventions
GSI-953
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
65 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Oct 4, 2026, 9:41 PM EDT
Completed Phase 4 Interventional

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

NCT05531591
View directory record Official record
Conditions
Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
Drug
Lead sponsor
Centre for Addiction and Mental Health
Other
Eligibility
60 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 4, 2026, 9:41 PM EDT
Not listed Not applicable Interventional

Evaluation of Programs of Coordinated Care and Disease Management

NCT00627029
View directory record Official record
Conditions
Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions
Care Coordination
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
Not listed
Enrollment
18,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 4, 2026, 9:41 PM EDT